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Because virtually all tissues contain blood vessels, the importance of hemevascularization 
has been long recognized in regenerative medicine and tissue engineering. However, the 
lymphatic vasculature has only recently become a subject of interest. Central to the task 
of growing a lymphatic network are lymphatic endothelial cells (LECs), which constitute 
the innermost layer of all lymphatic vessels. The central molecule that directs proliferation 
and migration of LECs during embryogenesis is vascular endothelial growth factor C 
(VEGF-C). VEGF-C is therefore an important ingredient for LEC culture and attempts to 
(re)generate lymphatic vessels and networks. During its biosynthesis VEGF-C undergoes 
a stepwise proteolytic processing, during which its properties and affinities for its interac-
tion partners change. Many of these fundamental aspects of VEGF-C biosynthesis have 
only recently been uncovered. So far, most—if not all—applications of VEGF-C do not 
discriminate between different forms of VEGF-C. However, for lymphatic regeneration 
and engineering purposes, it appears mandatory to understand these differences, since 
they relate, e.g., to important aspects such as biodistribution and receptor activation 
potential. In this review, we discuss the molecular biology of VEGF-C as it relates to the 
growth of LECs and lymphatic vessels. However, the properties of VEGF-C are similarly 
relevant for the cardiovascular system, since both old and recent data show that VEGF-C 
can have a profound effect on the blood vasculature.
Keywords: vascular endothelial growth factor C, lymphatic vessels, lymphedema, tissue engineering, A disintegrin 
and metalloproteinase with thrombospondin motifs 3, collagen and calcium binding eGF domains 1, growth 
factors, veGF receptors
iNTRODUCTiON
Lymphatic endothelial cells (LECs) form the innermost layer of lymphatic vessels, and they play 
a central role during the growth of the lymphatic system (Bautch and Caron, 2015). Lymphatic 
insufficiency can be the result of an underdeveloped lymphatic network (Butler et al., 2009), and 
hence the idea of growing lymphatic structures has been proposed early on as a potential treatment 
strategy for lymphedema (Karkkainen et al., 2001a; Saaristo et al., 2002). Irrespective of whether 
these structures are regrown in situ (Karkkainen et al., 2001b; Dai et al., 2010; Moriondo et al., 2010; 
Güç et al., 2017) or in vitro (Helm et al., 2007; Gibot et al., 2017; Knezevic et al., 2017), the growth 
and assembly of LECs into vessels and networks are central to the task of lymphatic engineering 
(Kanapathy et al., 2014; Schaupper et al., 2016).
Therefore, it is appropriate—when setting out to (re)construct lymphatic vessels—to get familiar 
with LEC proliferation, migration, assembly, and maintenance. The central growth factor that 
FiGURe 1 | VEGFs and VEGF receptors (VEGFRs). Each of the five mammalian VEGFs [PlGF, VEGF-A to -D], the viral VEGF-E, and the snake venom VEGF-F 
interacts specifically with a certain subset of the three VEGFRs. VEGF-CC156S is an engineered vascular endothelial growth factor C (VEGF-C) variant that interacts 
predominantly with VEGF receptor 3 (VEGFR-3) (Joukov et al., 1998). VEGFs that interact with all three receptors do not naturally exist, but have been engineered 
(Jeltsch et al., 2006). VEGF receptor 1 (VEGFR-1) and VEGF receptor 2 (VEGFR-2) are expressed on blood vascular endothelial cells (BECs), while VEGFR-2 and 
VEGFR-3 are expressed on lymphatic endothelial cells. VEGFR-3 is the primary mitogenic receptor for lymphatic endothelium, while VEGFR-2 is the primary 
mitogenic receptor for blood vascular endothelium. Exclusive to higher primates is the appearance of a short splice isoform of VEGFR-3 (VEGFR-3s) (Pajusola et al., 
1993; Borg et al., 1995; Hughes, 2001). Signaling pathways activated by VEGFR-3s are partially distinct from those activated by the long splice isoform (VEGFR-3l), 
since it lacks some of the phosphorylation sites required for mediator docking (e.g., for Shc-Grb2) (Fournier et al., 1995; Dixelius et al., 2003). The dotted arrows 
from VEGF-D indicate heterogeneous binding patterns. While mature human VEGF-D can activate VEGFR-2, this seems not to be the case for mouse VEGF-D 
(Baldwin et al., 2001), and consequently, VEGF-D function could have diverged since the evolutionary divide some 60–65 million years ago (O’Leary et al., 2013). 
Additionally, human VEGF-D can selectively lose its affinity for VEGFR-3 after proteolytic processing (Leppanen et al., 2011).
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mediates these tasks is vascular endothelial growth factor C 
(VEGF-C). While being a member of the VEGF family of growth 
factors, VEGF-C is in many aspects very different from the vas-
cular endothelial growth factor prototype VEGF-A.
veGFs AND veGF ReCePTORS (veGFRs)
The primary receptors of all VEGF family members are tyrosine 
kinase receptors. With certain exceptions (Olsson et al., 2006), 
they are only expressed by endothelial cells. However, all three 
VEGFRs (VEGFR-1, -2 and -3) are not equally distributed on 
endothelial cells. In the adult organism, VEGFR-3 expression is 
largely restricted to LECs (Kaipainen et al., 1995), while VEGFR-1 
expression is very low on LECs (Shibuya, 2001), and VEGFR-2 
can be found both on LECs and blood vascular endothelial cells 
(BECs) (Holmes et al., 2007). VEGFRs are activated by dimeri-
zation, which is achieved by the dimeric nature of the VEGF 
ligands. The two receptor binding epitopes of each VEGF ligand 
are composite epitopes and are absent in monomeric VEGF spe-
cies (Muller et al., 1997). Hence, monomeric VEGF species bind 
their respective receptors only with low affinity (Fuh et al., 1998) 
or not at all (Grunewald et al., 2010).
Apart from the VEGFRs, most VEGFs bind to co-receptors, 
which stabilize the VEGF/VEGFR interaction and increase the 
effective growth factor concentration on the cell surface, for 
example, neuropilins (Grunewald et  al., 2010), integrins (Soldi 
et  al., 1999), or syndecans (Johns et  al., 2016). However, these 
interactions are typically of lower affinity than the VEGF/VEGFR 
interaction (Soker et al., 2002).
In humans, five different genes encode VEGF family members: 
VEGFA, VEGFB, VEGFC, VEGFD, and PGF (placenta growth fac-
tor), respectively. Each VEGF can be roughly categorized as being 
hemangiogenic (VEGF-A, PlGF, and VEGF-B) or lymphangi-
ogenic (VEGF-C and VEGF-D). Unique to the hemangiogenic 
VEGFs is their interaction with VEGFR-1, while only members of 
the lymphangiogenic group do interact with VEGFR-3. VEGFR-
2, which is the receptor that drives proliferation and migration of 
BECs, can be activated by some but not all members from both 
groups (see Figure 1).
All VEGF family members are characterized by the central 
VEGF homology domain (VHD, aka PDGF/VEGF domain) 
FiGURe 2 | Biosynthesis and activation of vascular endothelial growth factor C (VEGF-C). VEGF-C is produced as an inactive propeptide. Proprotein convertases 
such as furin, PC5, or PC7 cleave between the VEGF homology domain and the C-terminal silk homology domain resulting in pro-VEGF-C. The silk homology 
domain is not removed by this cleavage, but remains covalently connected via cysteine bridges to the rest of pro-VEGF-C (Joukov et al., 1997b). Pro-VEGF-C is able 
to bind VEGFR-3, but does not activate it (Jeltsch et al., 2014). The second proteolytic cleavage by A disintegrin and metalloproteinase with thrombospondin motifs 
3 (ADAMTS3) removes both terminal domains resulting in mature, active VEGF-C. Cleavage by ADAMTS3 results in the major form of the mature VEGF-C, which is 
nine amino acids shorter compared to the minor form, which is likely a product of plasmin cleavage (Joukov et al., 1998; Baldwin et al., 2001; Jeltsch et al., 2014). 
Three N-glycosylation sites are found in VEGF-C (shown in green). Alternative names for different VEGF-C forms are given in brackets. The band pattern of VEGF-C 
produced from a full-length cDNA resolved by SDS-PAGE depends on the expressing cell line, expression levels and the antibody used for immunoprecipitation and/
or Western blotting. 3T3 fibroblasts produce almost exclusively pro-VEGF-C. In high-level-expressing CHO cells, a significant fraction of the secreted protein can 
remain unprocessed. Among the most efficiently processing cells are 293 cells, but pro-VEGF-C still represents the majority of the VEGF-C protein.
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(EMBL-EBI, 2017). The VHD contains the receptor binding 
domain and features a pattern of characteristically spaced cysteine 
residues, which gives rise to a cystine knot (Holmes and Zachary, 
2005). In addition to the VHD, most VEGFs feature accessory 
sequences that further delineate the specific properties of indi-
vidual VEGFs: the affinity of, e.g., VEGF-A to the co-receptors 
neuropilin-1 and -2 (NP-1 and NP-2) (Neufeld et al., 2002), or of 
VEGF-C to the co-receptor NP-2 (Karpanen et al., 2006; Xu et al., 
2010), heparan sulfate proteoglycans (HSPGs) (Johns et al., 2016), 
and to the extracellular matrix (Jha et al., 2017). In VEGF-C and 
VEGF-D, the N- and C-terminal accessory sequences are excep-
tionally long and function as propeptides, which fold into own 
domains (see Figure 2) and need to be removed for activation by 
two proteolytic cleavages.
While only five genes encode the mammalian VEGFs, the 
actual number of different VEGFs is much larger. Within the 
hemangiogenic VEGFs, functional diversity is generated mostly 
by alternative splicing, resulting in differences in the affinity for 
HSPGs (“heparin affinity”) (Robinson and Stringer, 2001). For 
VEGF-C, no functions have been assigned yet to the described 
alternative splice variants (Lee et al., 1996; Ensembl, 2016).
THe LYMPHANGiOGeNiC veGFs
Vascular endothelial growth factor C was discovered more than 
20  years ago as a binding partner of VEGFR-3 from the cell 
culture supernatant of the human prostate cancer cell line PC3 
(Joukov et al., 1996). In the same year, also murine VEGF-C was 
described and initially named VRP (VEGF-related protein) (Lee 
et al., 1996). The specific lymphangiogenic properties of VEGF-C 
were demonstrated in various animal models (Jeltsch et al., 1997; 
Oh et al., 1997). VEGF-D is the second member of the lymphangi-
ogenic VEGF subgroup. It was discovered independently by three 
research teams and named once FIGF (c-fos-induced growth 
factor) (Orlandini et  al., 1996) and twice VEGF-D (Yamada 
et al., 1997; Achen et al., 1998). Both VEGF-C and VEGF-D use 
posttranslational modification by proteolytic cleavage to generate 
molecular species diversity (Joukov et al., 1997b; Stacker et al., 
1999), but the proteases are different (Bui et  al., 2016). While 
VEGF-D shares many similarities with VEGF-C, it cannot replace 
VEGF-C (see the VEGF-D paragraph).
DiFFeReNT veGF-C FORMS, THe veGF-
CC156S MUTANT AND ANGiOGeNiC “SiDe 
eFFeCTS”
The most prominent differences between the different 
VEGF-C forms are the affinities for the receptors, co-recep-
tors, and the extracellular matrix. With increasing processing 
(see Figure  2), VEGF-C’s affinity for both VEGFR-2 and 
VEGFR-3 increases, and fully processed mature VEGF-C 
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is therefore not only lymphangiogenic but also angiogenic 
(Joukov et al., 1997a; Anisimov et al., 2009) and induces the 
permeability of blood vessels (Joukov et al., 1997b). To identify 
which functions of VEGF-C are mediated by which receptor 
(VEGFR-2 versus VEGFR-3), the VEGF-CC156S mutant was 
developed (Joukov et al., 1998) (commercially available from 
R&D systems as 752-VC or its rat homolog from Reliatech as 
R20-016). This mutant largely lacks VEGFR-2 affinity and 
can therefore be used to exclude VEGF-C effects on the blood 
vasculature (Veikkola et al., 2001). However, despite its dual 
receptor binding, the effect of wild type VEGF-C on the blood 
vasculature is minimal in many models, and recent data sug-
gest that the localization of pro-VEGF-C on LEC surfaces prior 
to activation could explain this specificity (Jha et  al., 2017). 
Most reports that attribute a prominent angiogenic effect to 
VEGF-C have investigated prenatal development (Oh et  al., 
1997; Lohela et al., 2008) or used VEGF-C forms lacking the 
propeptides (Oh et  al., 1997; Cao et  al., 1998; Sweat et  al., 
2014). The propeptides keep VEGF-C inactive (Joukov et al., 
1997b), are required for localizing VEGF-C (Jha et al., 2017), 
and are removed by sequential proteolysis by furin (Siegfried 
et  al., 2003) and A disintegrin and metalloproteinase with 
thrombospondin motifs 3 (ADAMTS3) (Jeltsch et  al., 2014) 
or plasmin (McColl et al., 2003).
The relationship between affinity and receptor activation is 
not straightforward: pro-VEGF-C is able to bind VEGFR-3 under 
cooperation of NP-2 without any detectable receptor activation. 
In fact, it is even a competitive inhibitor of mature VEGF-C for 
VEGFR-3 activation (Jeltsch et al., 2014).
veGF-D
VEGF-D is the closest paralog of VEGF-C (Achen et al., 1998). 
The angiogenic potential of mature VEGF-D has been shown 
to be stronger compared to mature VEGF-C (Rissanen et  al., 
2003), which is explained by the fact that maximally processed 
VEGF-D exclusively binds to VEGFR-2, while VEGF-C retains 
in its maximally processed form the capacity to bind VEGFR-3 
(Leppanen et al., 2011). It is differently activated than VEGF-C 
(Bui et  al., 2016), and because the proteolytic environment 
is difficult to predict and control, the use of VEGF-D for LEC 
stimulation remains problematic. Moreover, Vegfd gene-deleted 
mice have no lymphatic phenotype arguing for no major role in 
the development of the murine lymphatic system (Baldwin et al., 
2005).
ReQUiReMeNT FOR COLLAGeN AND 
CALCiUM BiNDiNG eGF DOMAiNS 1 
(CCBe1) AND ADAMTS3
The two molecules that are required for the proteolytic activa-
tion of VEGF-C are the CCBE1 protein and the ADAMTS3 
protease. ADAMTS3 catalyzes the final step in the proteolytic 
processing of VEGF-C, removing the N-terminal propeptide and 
releasing the fully active, mature VEGF-C (Jeltsch et  al., 2014; 
see Figure 2). In vitro, large amounts of ADAMTS3 are able to 
activate pro-VEGF-C, but in vivo, ADAMTS3 requires the assis-
tance of CCBE1 for the efficient activation of VEGF-C. CCBE1 
enhances the VEGF-C activation by two different mechanisms: 
it increases the processivity of the ADAMTS3 enzyme (Roukens 
et al., 2015) and it colocalizes VEGF-C and ADAMTS3 on cell 
surfaces and ECM to form the trimeric activation complex (Bui 
et al., 2016; Jha et al., 2017). Similar to Vegfc, the genetic ablation 
of either Ccbe1 or Adamts3 in mice results in a general halt of 
lymphatic development (Bos et al., 2011; Hagerling et al., 2013; 
Janssen et al., 2015).
A disintegrin and metalloproteinase with thrombospondin 
motifs 3 cleavage results in the so-called “major” form of mature 
VEGF-C (Joukov et al., 1998; Jeltsch et al., 2014). The so-called 
“minor” form is nine amino acids longer at its N-terminus and 
is presumably generated by plasmin. Plasmin might activate 
VEGF-C during wound healing and inflammatory processes 
(McColl et al., 2003), where it could rapidly release large amounts 
of active VEGF-C from matrix-bound, “latent” pro-VEGF-C. 
However, it is still unclear, whether there is any difference 
between the lymphangiogenesis response to the “major” and 
“minor” forms of mature VEGF-C.
To bypass the complex proteolytic maturation of VEGF-C, the 
recombinant production of mature VEGF-C is almost exclusively 
done from a truncated cDNA. However, this is not without 
problems, since VEGF-C contains in its VHD—as opposed to 
VEGF-A—an extra cysteine residue (Cys 137), which interferes 
with intermolecular disulfide bond formation (Chiu et al., 2014) 
and protein stability (Anisimov et al., 2009; Leppanen et al., 2011) 
(see Figure 3). It has been proposed that when produced from a 
full-length cDNA, cysteine residues from the VEGF-C propep-
tides could protect Cys 137 and thus facilitate correct disulfide 
bond formation in the VHD.
THe eNiGMATiC “SiLK HOMOLOGY” 
DOMAiN
Very intriguing is the repetitive arrangement of cysteine residues 
(CX10CXCXC) in the C-terminal propeptide of VEGF-C. This 
signature is unique within vertebrate proteins, and its phyloge-
netic origin remains unknown. Except in VEGF-C, it occurs, 
e.g., in the balbiani ring protein 3 and salivary proteins of silk 
weaving mosquito larvae of the genus Chironomus (Dignam 
and Case, 1990). Therefore, the term “silk homology domain” 
was coined to describe the C-terminal propeptide (Joukov et al., 
1996). In addition to regulating the activity of VEGF-C, this 
domain endows the molecule with most of its heparin affinity 
(Johns et al., 2016), and it is the determining factor for the ECM 
sequestration of VEGF-C (Jha et al., 2017). Interestingly, seques-
tration and proteolysis-mediated release of active VEGF-C have 
also been reverse engineered by concatenating a fibrin-binding 
(FB) and a MMP-degradable polypeptide sequence N-terminally 
to the mature VEGF-C sequence (Güç et al., 2017). This protein 
(FB-VEGF-C) compared favorably to mature VEGF-C in the 
local induction of lymphangiogenesis, but native sequestration 
of wild-type VEGF-C expressed from a full-length cDNA was not 
included in this comparison.
FiGURe 3 | Alignment of human, mouse, and rat vascular endothelial growth factor C (VEGF-C)/D with human VEGF-A. The sequences of the active, mature 
VEGF-C/D are boxed gray. Proteolytic cleavage sites and enzymes (if known) are indicated in blue colors. The signal peptide is boxed green. The eight conserved 
cysteines of the PDGF/VEGF signature (Muller et al., 1997) are boxed yellow and intra- and intermolecular disulfide bridges are indicated by black connecting lines. 
VEGF-C/D-specific conserved cysteine residues are boxed in orange. The two asterisks denote the only two amino acid residues that are different between fully 
processed mouse and human VEGF-C. Cysteine 156, which is mutated to serine in the VEGFR-3-monospecific variant VEGF-CC156S, participates in the 
intermolecular cystine bridge (Joukov et al., 1998). When mature VEGF-C is produced from a truncated cDNA, the single cysteine 137 remains unpaired decreasing 
protein stability (Anisimov et al., 2009; Leppanen et al., 2011). When pairing with cysteine 156, cysteine 137 interferes with intermolecular disulfide bond formation 
and protein folding, explaining the observation of significant amounts of single-linked dimers, non-covalent VEGF-C dimers and VEGF-C monomers (Joukov et al., 
1996; Jeltsch et al., 2006; Chiu et al., 2014). Above the alignment, a heat map indicates the areas of highest divergence, deduced from a more comprehensive 
alignment of VEGF-A, -C, and -D. The C-terminal domains of VEGF-C/D are not shown.
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ReGULATiON OF veGF-C SiGNALiNG
Compared to VEGF-A, not much is known about the regulation 
of VEGF-C expression in vivo. The fact that VEGF-C is produced 
as an inactive precursor (pro-VEGF-C) indicates that much of its 
regulation happens after its constitutive secretion at the level of 
proteolytic activation. However, while the activation mechanism 
itself has been studied extensively (Jeltsch et al., 2014; Roukens 
et al., 2015; Bui et al., 2016; Jha et al., 2017), virtually nothing is 
known about the regulation of the obligatory protease ADAMTS3 
and its cofactor CCBE1.
In the adult organism, inflammation potently upregulates 
VEGF-C expression, most notably by macrophages (Ristimäki 
et  al., 1998; Baluk et  al., 2005; Krebs et  al., 2012), resulting in 
a negative feedback loop (Zhou et al., 2011; Christiansen et al., 
2016) promoting resolution in some models, while aggravating 
the situation in others (Kim et al., 2014).
The interstitial pressure that builds up during development 
in blood-vascularized but lymphatic-free tissues leads via 
β1-integrin-mediated mechanoinduction to enhanced VEGFR-3 
phosphorylation (Planas-Paz et  al., 2012). However, it remains 
unclear, whether meaningful VEGFR-3 phosphorylation can 
happen in vivo entirely without ligand, although the kinase activ-
ity of VEGFR-3 is dispensable in vitro (Galvagni et al., 2010). In 
any case, the interplay of mechanical forces with growth factor 
signaling for the establishment of functional lymphatic networks 
has been shown in many systems (Sabine et al., 2016). Binding of 
mature VEGF-C to VEGFR-3 results in the activation of both the 
MAPK/ERK and AKT intracellular signaling pathways (Mäkinen 
et al., 2001; Deng et al., 2015), which promote survival, growth, 
and migration in LECs (Mäkinen et al., 2001).
veGF-C SiGNALiNG iN eMBRYONiC 
DeveLOPMeNT
VEGF receptor 3 was discovered before VEGF-C and VEGF-D, 
and therefore, VEGFR-3 was between 1992 and 1996 an “orphan 
TABLe 1 | Hereditary human lymphedema conditions involving the vascular endothelial growth factor C (VEGF-C)/VEGF receptor 3 (VEGFR-3) signaling pathway.




Reference for the 
initial linkage
Molecular etiology viable animal models
FLT4 (VEGFR-3) Hereditary lymphedema 







Dominant negative inactivation of the 
intracellular kinase domain (Irrthum 
et al., 2000; Karkkainen et al., 2000)
Chy mice (inactivating Flt4 mutation) 
(Karkkainen et al., 2001b); VEGFR-3 
inhibition (Mäkinen et al., 2001)
VEGFC (VEGF-C) Hereditary lymphedema 





Secretion defect (Gordon et al., 2013; 
Villefranc et al., 2013)
Chy-3 mice (hemizygous Vegfc 
deletion) (Dellinger et al., 2007); 






Hennekam syndrome type 
1 (235510)
Generalized
Alders et al. (2009) A disintegrin and metalloproteinase 
with thrombospondin motifs 3 
activation defect (Jeltsch et al., 2014; 
Roukens et al., 2015), localization 
defect (Jha et al., 2017)










Hennekam syndrome type 
2 (616006)
Alders et al. (2014) Unknown molecular etiology Vascular abnormalities were not 
reported for the full Fat4 ko mice 







Hennekam syndrome type 3 Brouillard et al. 
(2017)
Secretion defect (Brouillard et al., 
2017), localization defect (Jha et al., 
2017)
Conditional Adamts3 ko mice (Bui 
et al., 2016)
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receptor”, i.e., a receptor without known ligand. However, soon 
after the discovery of VEGFR-3, the specific expression pattern 
of VEGFR-3 suggested that its function was closely related to the 
lymphatic system. In the early stages of embryonic development, 
all endothelial cells express VEGFR-3, but its expression becomes 
progressively restricted to LECs (Kaipainen et al., 1995). Finally, 
VEGFR-3 expression becomes sufficiently specific for LECs that 
it has been used to identify LECs (Petrova et al., 2008), despite 
the existence of other VEGFR-3 expressing endothelial cells, e.g., 
angiogenic, sinusoidal, and fenestrated BECs.
The pivotal role of the VEGFR-3 ligand VEGF-C in the estab-
lishment of the lymphatic vasculature is witnessed by the fact that 
mice devoid of VEGF-C do not develop any lymphatic structures 
and form generalized edema from E12.5, resulting in embryonic 
death around E16.5 (Karkkainen et al., 2004).
Interestingly, mice devoid of the VEGF-C receptor VEGFR-3 
die already around E9.5, before the first lymphatic structures 
develop, from failures in the organization and maturation of 
blood vessels (Dumont et al., 1998). However, embryonic lethality 
after deletion of both VEGFR-3 ligands, VEGF-C and VEGF-D, 
occurs only around E16.5, suggesting no role of these ligands 
for VEGFR-3 activation in early embryogenesis (Haiko et  al., 
2008). Since VEGFR-3 can form heterodimers with VEGFR-2, 
this might be a substitute mechanism for VEGFR-3 activation 
(Dixelius et al., 2003; Nilsson et al., 2010). Alternatively, ligand-
less baseline signaling (Zhang et al., 2005; Galvagni et al., 2010), 
mechanoinduction (Planas-Paz et  al., 2012), or unrecognized 
ligands might provide a sufficient stimulus. Interestingly, nei-
ther the development of the blood vascular system nor of the 
lymphatic vascular system is affected by the lack of the second 
lymphangiogenic growth factor VEGF-D (Baldwin et al., 2005).
GeNeTiC LeSiONS iN THe veGF-C/
veGFR-3 SiGNALiNG PATHwAY
So far, mutations in 27 genes have been found to cause human 
lymphedema conditions. Several of these mutations affect com-
ponents of the VEGF-C/VEGFR-3 signaling pathway (Table 1). 
Interestingly, a major fraction of hereditary lymphedema patients 
present with mutations in VEGFR-3, while mutations in the other 
genes are relatively rare (Brouillard et al., 2014, 2017).
Although in hereditary lymphedema type 1A and 1D, all cells 
carry the mutant VEGFR-3 or VEGF-C gene, not all lymphatic 
vessels and body parts are equally affected. Hypoplastic or aplas-
tic lymph capillaries are mainly found in peripheral, superficial 
regions (Bollinger et al., 1983). However, in addition to the under-
developed lymphatic structures, a functional deficit seems to play 
a variable, but significant role in the manifestation of the edema 
(Mellor et  al., 2010). A higher hydrostatic pressure resulting in 
increased drainage needs in the extremities could possibly explain 
localized symptoms. However, leg edema is as well observed in 
mice and newborns, where hydrostatic pressure differences are 
negligible (Karkkainen et al., 2001a). Alternatively, LECs from dif-
ferent vascular beds could have a different sensitivity for VEGFR-3 
signaling, perhaps due to a different developmental origin.
LeC CULTURe AND veGF-C SiGNALiNG
During embryonic growth, signaling by VEGF-C is necessary 
for the establishment of the lymphatic vasculature (Karkkainen 
et al., 2004). In the adult organism, the dependency on VEGF-C 
is less pronounced, and ablation of VEGF-C in the adult organ-
ism appears well tolerated also over longer periods of time, 
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except for the intestinal lymphatics (the lacteals) and meningeal 
lymphatics, which depend on a steady supply with VEGF-C 
(Nurmi et al., 2015; Antila et al., 2017). It is not known, whether 
this difference is due to the higher stress or increased turnover 
of intestinal LECs compared to, e.g., adult skin LECs, which are 
mostly in the resting phase (Alexander et al., 2010). Despite the 
apparent VEGF-C requirements for proliferating LECs in vivo, 
LEC vendors specifically endorse only the use of the hemangio-
genic VEGF-A for LEC culture. However, some researchers have 
modified such media to contain VEGF-C (Mäkinen et al., 2001; 
Petrova et  al., 2002; Podgrabinska et  al., 2002; Veikkola et  al., 
2003). While serum does typically contain VEGF-C in the single 
digit ng/ml-range (R&D Systems, 2017), serum-supplemented 
LEC culture medium would still contain only small amounts 
of VEGF-C compared to VEGF-A, which stimulates VEGFR-2, 
but not VEGFR-3. While VEGF-A stimulates LEC proliferation 
and lymphatic vessel dilation in vitro (Dellinger and Brekken, 
2011) and increases the density of lymphatic in vitro capillary 
networks (Marino et al., 2014) to a similar degree as VEGF-C, 
its importance for in vivo LEC proliferation is arguable as only 
very few in vivo models of VEGF-A application seem to directly 
affect lymphatic networks (Shin et al., 2008). While VEGFR-2 
and VEGFR-3 activation both result in PKC-dependent Akt 
phosphorylation, the activation routes and kinetics differ 
(Mäkinen et  al., 2001). Importantly, SOX18 and KLF4, which 
are implicated in LEC differentiation (Francois et al., 2008; Park 
et al., 2014), are specifically regulated by VEGFR-3 (Dieterich 
et al., 2017).
The specific form of VEGF-C that is used for LEC culture 
supplementation is the active, mature form, but pro-VEGF-C 
also might be an attractive option, since the LEC-expressed 
ADAMTS3 and CCBE1 (Jha et al., 2017) would concertedly con-
vert it into the mature form, providing a differently localized and 
perhaps more sustained stimulus. Due to its potent synergistic 
effect with VEGF-C, hepatocyte growth factor (HGF) also needs 
consideration as a LEC culture additive (Kajiya et al., 2005; Gibot 
et al., 2016).
wHeN veGF-C iS NOT eNOUGH
While in some models, the angiogenic component of VEGF-C 
can be exposed (e.g., in the heart) (Losordo et al., 2002; Chen 
et al., 2014), VEGF-C predominantly affects the lymphatic sys-
tem. Not surprisingly, most therapeutic applications of VEGF-C 
are targeting the lymphatics (Tammela et  al., 2007; Honkonen 
et  al., 2013; Klotz et  al., 2015), and VEGF-C should therefore 
be considered the primary growth factor of choice in lymphatic 
engineering tasks that involve LECs. While necessary, VEGF-C 
alone is not sufficient for the successful establishment of a func-
tional lymphatic network in some situations (Goldman et  al., 
2005), and blocking signals that inhibit lymphangiogenesis such 
as TGF-β1 (Avraham et al., 2010) might be necessary. An elegant 
way bypassing the need for VEGF-C supplementation is the 
coculture of LECs with other cell types. In addition to secreted 
factors, cell–cell contacts appear important for the establish-
ment of lymphatic networks. In one model, lymphangiogenesis 
was sustained by fibroblast-derived VEGF-C and HGF. While 
VEGF-C appeared to be constitutively expressed by fibroblasts, 
HGF expression was induced only in the cocultures (Gibot et al., 
2016). Whether the fibroblasts were also able to stimulate the 
release of Reelin from the LECs was not analyzed in this model. 
Reelin release from LECs is normally induced by smooth muscle 
cell contacts and is required for the establishment of collecting 
vessels (Lutter et al., 2012). In another coculture model, LECs, 
BECs, and adipose-derived stromal cells (ASCs) in a 3D fibrin 
matrix depended on the addition of exogenous VEGF-C for sub-
stantial LEC network formation in addition to cell–cell contacts 
between LECs and ASCs (Knezevic et  al., 2017). In the same 
model, BEC network formation was not affected by the absence 
of exogenous VEGF-C.
DiReCTiNG ReGeNeRATive LYMPHATiC 
GROwTH IN VIVO
The mechanisms of the directional growth are similar for blood 
vessels and nerve cell axons (Carmeliet, 2003): a specialized 
cell on the tip of the vascular sprout (tip cell) determines the 
direction of growth of subsequent cells (stalk cells) by extend-
ing filopodia with growth factor receptors (Gerhardt et  al., 
2003). However, in vivo evidence for the importance of VEGF 
gradients for the directed growth of vascular networks is sparse 
(Ruhrberg et al., 2002), and also in vitro, convincing evidence 
is largely absent (Bautch, 2012). Likewise, filopodia seems to 
be dispensable for vascular patterning (Wacker et al., 2014). In 
the expansion of lymphatic networks, similar directed sprout-
ing can be observed, but e.g. in the mouse tail lymphedema 
model, the mere application of VEGF-C was not enough to 
induce sprouting lymphangiogenesis (Goldman et  al., 2005). 
Moreover, and contrary to expectations, VEGF-C levels corre-
lated even in some models with lymphedema formation, appar-
ently via inducing vascular leakage and immune cell infiltration 
(Gousopoulos et  al., 2017). Surgical grafting of engineered 
small lymphatic structures is difficult unless they are grafted as 
part of a larger tissue (e.g., a vascularized skin graft). Hence, the 
idea of generating lymphatics in situ is attractive and indeed has 
been successfully achieved in some animal models using differ-
ent delivery strategies for VEGF-C (Karkkainen et al., 2001b; 
Szuba et  al., 2002; Yoon et  al., 2003). The question whether 
VEGF-C alone is enough (Breier, 2005; Goldman et al., 2005) 
has recently at least received a partial answer by the discovery 
of obligatory cofactors such as CCBE1 and ADAMTS3 for cor-
rect VEGF-C localization and efficient activation (Jeltsch et al., 
2014; Jha et  al., 2017), and the presence or absence of these 
factors might explain differences in the lymphatic response. 
After encouraging preclinical studies (Tammela et  al., 2007), 
the therapeutic value of VEGF-C for an improved integration 
of transplanted lymph nodes into the regional lymph system 
is currently under investigation (Tervala et al., 2015). It is less 
obvious how large collecting lymphatics could be generated 
in  situ, but flow-stimulated remodeling of smaller lymphatics 
might happen akin to the hemodynamic remodeling of blood 
vessels (Culver and Dickinson, 2010).
FiGURe 4 | Vascular endothelial growth factor C (VEGF-C) induces specifically the growth of the lymphatic vasculature. Whole-mount LYVE-1 staining of mouse 
ears 2 weeks after adenoviral transduction with VEGF-C (A) and LacZ (B). AdVEGF-C induces hyperplasia of and neo-sprouting from the lymphatic vasculature. 
Arrows indicate lymphatic sprouting. Bar, 100 µm.
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FiGURe 5 | Works that give important insights into vascular endothelial growth factor C (VEGF-C) and its function grouped according to topic. Publications about 
the use of VEGF-C specifically in lymphatic tissue engineering are not included since this list tries to highlight the elemental scientific insights on which tissue 
engineering can build.
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